Triple Negative Breast Cancer By Jaya Ghosh
SESSION 3 : TRIPLE NEGATIVE BREAST CANCER
Chairpersons :
R. Gopal, Manohar Chari, N. Sudhakar
Reviewer :
Jaya Ghosh
1. Increasing the dose density of adjuvant chemotherapy by shortening intervals
between courses or by sequential drug administration significantly reduces both
disease recurrence and breast cancer mortality: An EBCTCG meta-analysis of 21,000
women in 16 randomised trials
Author: Gray R.
Citation: SABCS ABSTRACT GS1-01
2. NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant
chemotherapy with Adriamycin (A) and Cyclophosphamide (C) ® Weekly Paclitaxel
(WP), or Docetaxel (T) and C with or without a year of Trastuzumab (H) in women with
node-positive or high-risk node-negative Invasive Breast Cancer (IBC) expressing HER2
staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC)
Author: Fehrenbacher L.
Citation: SABCS ABSTRACT GS1-02
3.Prospective WSG phase III plan B trial: Final analysis of adjuvant 4xEC®4x doc vs. 6x
docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-tohigh
genomic risk HER2-negative, early breast cancer
Author: Nadia Harbeck
Citation: ASCO Abstract 504 Journal of Clinical Oncology 35, no. 15_suppl (May 2017)
504-504